Related Experiment Video
Updated: Oct 3, 2025
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
602
Multi-Level Computational Modeling of Anti-Cancer Dendritic Cell Vaccination Utilized to Select Molecular Targets for
Xin Lai1,2, Christine Keller1, Guido Santos1,3
1Laboratory of Systems Tumor Immunology, Department of Dermatology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Frontiers in Cell and Developmental Biology
|February 21, 2022
Summary
Computational modeling of dendritic cells (DCs) enhances cancer immunotherapy by simulating DC life cycles and optimizing molecular targets for improved cytotoxic T lymphocyte (CTL) responses in DC vaccination.
Area of Science:
- Computational Biology
- Immunology
- Bioinformatics
Background:
- Dendritic cells (DCs) are crucial for therapeutic cancer vaccination, mediating tumor-antigen presentation to cytotoxic T lymphocytes (CTLs).
- Efficient induction of durable CTL responses by DCs is essential for successful anti-cancer immunotherapy.
- Computational modeling offers a powerful approach to understand DC-mediated CTL induction and optimize DC vaccination strategies.
Purpose of the Study:
- To develop a comprehensive, multi-level computational model simulating the life cycle of DCs in anti-cancer immunotherapy.
- To identify molecular targets for enhancing DC-mediated immunogenicity and optimizing DC vaccination therapies.
- To explore strategies for improving therapeutic DC vaccination against cancer, focusing on molecular optimization.
Main Methods:
- Development of a multi-level model encompassing DC spreading, bio-distribution, maturation, activation, and CTL activation.
- Calibration of the model using quantitative experimental data on DC molecular circuits, bio-distribution, and DC-T cell interactions.
- Application of sensitivity analysis and simulations to identify molecular targets for enhancing anti-cancer DC vaccination.
Main Results:
- The developed data-driven model accurately represents key stages of DC immunotherapy.
- Simulations identified potential molecular targets and strategies for enhancing DC-mediated immunogenicity.
- The model provides insights into the concerted modulation of intracellular regulatory processes for improved DC vaccination.
Conclusions:
- A comprehensive, time-resolved, multi-level model for studying DC vaccination in melanoma has been established.
- The model serves as a valuable tool for identifying molecular targets to optimize DC-based cancer therapy.
- Findings suggest avenues for enhancing DC-mediated immunogenicity, requiring further in vitro and in vivo validation.
Related Concept Videos
01:27Tumor Immunotherapy
708
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
708
01:30Cancer Vaccines
542
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
542